Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/33129
DC FieldValue
dc.titleBevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma
dc.contributor.authorHuynh, H.
dc.contributor.authorYu, K.
dc.contributor.authorWu, J.
dc.contributor.authorLee, M.H.
dc.contributor.authorHor, H.
dc.contributor.authorSoo, K.C.
dc.contributor.authorToh, H.C.
dc.contributor.authorTan, P.
dc.contributor.authorSalto-Tellez, M.
dc.contributor.authorChow, P.K.H.
dc.contributor.authorLee, C.K.
dc.contributor.authorSoong, R.
dc.contributor.authorGoh, B.C.
dc.contributor.authorLee, H.S.
dc.contributor.authorSomani, A.
dc.contributor.authorTan, P.H.
dc.contributor.authorPalanisamy, N.
dc.contributor.authorKalpana, R.
dc.date.accessioned2012-05-29T02:20:50Z
dc.date.available2012-05-29T02:20:50Z
dc.date.issued2008
dc.identifier.citationHuynh, H., Yu, K., Wu, J., Lee, M.H., Hor, H., Soo, K.C., Toh, H.C., Tan, P., Salto-Tellez, M., Chow, P.K.H., Lee, C.K., Soong, R., Goh, B.C., Lee, H.S., Somani, A., Tan, P.H., Palanisamy, N., Kalpana, R. (2008). Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. Journal of Hepatology 49 (1) : 52-60. ScholarBank@NUS Repository.
dc.identifier.issn01688278
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/33129
dc.description.abstractBackground/Aims: Hepatocellular carcinoma is a leading cause of global cancer mortality, with standard chemotherapy being minimally effective in prolonging survival. We investigated if combined targeting of vascular endothelial growth factor protein and expression might affect hepatocellular carcinoma growth and angiogenesis. Methods: We treated patient-derived hepatocellular carcinoma xenografts with (i) bevacizumab; (ii) rapamycin; and (iii) bevacizumab plus rapamycin. Western blotting was employed to determine changes in the proteins. Apoptosis, vascular endothelial growth factor expression, microvessel density, and cell proliferation were analyzed by immunohistochemistry. Results: Hepatocellular carcinoma growth was inhibited by bevacizumab plus rapamycin treatment to a significantly greater degree than bevacizumab or rapamycin monotherapy. Reductions in tumor growth by bevacizumab plus rapamycin were associated with inhibition of downstream targets of the mammalian target-of-rapamycin pathway, reductions in vascular endothelial growth factor expression, and tumor microvessel density. Potentially additive effects of bevacizumab plus rapamycin included reductions in vascular endothelial growth factor expression, cyclin D1, and cyclin B1. In an intra-peritoneal model of hepatocellular carcinoma, bevacizumab plus rapamycin potently inhibited both intra-liver and intra-abdominal tumor growth, reduced ascites levels, and significantly prolonged mouse survival. Conclusions: Bevacizumab and rapamycin, which are both clinically approved drugs, may represent a novel molecularly-targeted combination treatment for hepatocellular carcinoma. © 2008 European Association for the Study of the Liver.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.jhep.2008.02.022
dc.sourceScopus
dc.subjectAngiogenesis
dc.subjectLiver cancer
dc.subjectmTOR inhibition
dc.subjectTreatment
dc.subjectXenografts
dc.typeArticle
dc.contributor.departmentPHARMACOLOGY
dc.contributor.departmentPATHOLOGY
dc.contributor.departmentNATIONAL UNIVERSITY MEDICAL INSTITUTES
dc.description.sourcetitleJournal of Hepatology
dc.description.volume49
dc.description.issue1
dc.description.page52-60
dc.description.codenJOHEE
dc.identifier.isiut000257484300008
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

65
checked on Mar 8, 2018

WEB OF SCIENCETM
Citations

61
checked on Dec 31, 2018

Page view(s)

118
checked on Aug 10, 2019

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.